Assessment of hypervolemia by cyclic 3 ` 5 `-guanosine monophosphate in pediatric patients on hemodialysis by Sitter, Thomas et al.
Letter to the Editor
Nephron 1999;83:287–288
Assessment of Hypervolemia by Cyclic
3’5’-Guanosine Monophosphate in
Pediatric Patients on Hemodialysis
Thomas Sittera Verena Holzgartnera Gernot Wolframb Marcel Toepfera Bernd Klarec
Rupert Gerzerb Helmut Schiffla
aDepartment of Nephrology, Medizinische Klinik, Klinikum Innenstadt, Ludwig-Maximilians-Universität München,
bDeutsches Zentrum für Luft- und Raumfahrtmedizin, Köln, und cPediatric Dialysis Unit,
Technische Universität München, Deutschland
Dr. Thomas Sitter
Medizinische Klinik, Klinikum Innenstadt der Universität München
Ziemssenstrasse 1
D–80336 München (Germany), Tel. +49 89 5160 2129
Fax +49 89 5160 4924, E-Mail Thomas.Sitter@medinn.med.uni-muenchen.de
ABC
Fax + 41 61 306 12 34
E-Mail karger@karger.ch
www.karger.com
© 1999 S. Karger AG, Basel
0028–2766/99/0833–0287$17.50/0
Accessible online at:
http://BioMedNet.com/karger
Dear Sir,
The exact determination of the hydration
state represents one of the central problems
of maintenance hemodialysis therapy [1].
Usually, clinical signs, radiological features
on chest X-ray and echocardiography are
used for the determination of dry body
weight. However, these criteria are relatively
insensitive and, as a consequence, a consid-
erable number of hemodialysis patients re-
main overhydrated. In children with end-
stage renal disease assessment of dry body
weight is particularly difficult. Weight gain
may be interpreted as growth although it
might be caused by sodium and water reten-
tion.
Extracellular fluid volume overload is
the major stimulus for secretion of atrial
natriuretic peptide (ANP) and its second
messenger cyclic 3)5)-guanosine monophos-
phate (cGMP). In a number of studies we
have shown that plasma cGMP levels are
reliable markers for fluid overload in adults
on renal replacement therapy with normal
heart function [2–4]. In order to test the abil-
ity of cGMP as a possible biochemical mark-
er for fluid overload in children, we designed
a prospective longitudinal study. Pre- and
postdialytic cGMP concentrations were
measured over a period of 9 months (9
repeated measurements for each patient) in
15 children and adolescents (9 males, 6 fe-
males) with end-stage renal disease treated
by intermittent hemodialysis (4 h three
times per week). The age ranged between 8
and 19 years with a mean age of 15 B 3
years. The primary kidney diseases were dys-
plastic kidneys (5 patients), glomerulone-
phritis (3 patients), nephronophtisis (2 pa-
tients), amyloidosis (2 patients), Alport’s
syndrome (1 patient), hyperoxaluria (1 pa-
tient) and polycystic kidney disease (1 pa-
tient). The ideal body dry weight was esti-
mated in all patients at the beginning of the
study by clinical means, echocardiography,
vena cava diameter and chest X-ray. Fifteen
healthy sex- and age-matched children and
adolescents served as controls. cGMP was
determined in alcohol-extracted plasma by
radioimmunoassay as has been described in
detail previously [5].
Compared with healthy controls, the pre-
dialytic plasma concentrations of cGMP
were markedly elevated in all 15 volume-
expanded hemodialyzed children (16.8 B
7.1 vs. 4.2 B 1.8 pmol/ml; p ! 0.05). Before
hemodialysis, the mean body weight ex-
ceeded the estimated dry weight by 1.8 B
0.6 kg. The circulating cGMP values in these
patients were influenced by their residual
renal function: children with daily urinary
excretion over 200 ml had significantly low-
er predialytic plasma cGMP levels than did
those with anuria (13.3 B 5.6 vs. 23.4 B
4.3 pmol/ml; p ! 0.05). In contrast, postdia-
lytic cGMP values were not influenced by
urinary volume (6.6 B 2.3 vs. 6.2 B
2.7 pmol/ml).
Removal of excess body fluid during he-
modialysis resulted in a significant decrease
in cGMP values (6.7 B 2.2 vs. 16.8 B
7.1 pmol/ml; p ! 0.05) (fig. 1A). However,
postdialytic cGMP levels were still signifi-
cantly higher than in normal controls (6.7 B
2.2 vs. 4.2 B 1.8 pmol/ml; p ! 0.05). None of
our studied patients had on an average a
postdialytic cGMP concentration over
10 pmol/ml during the 9-month follow-up.
As shown in figure 1B, the reduction in body
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weight during hemodialysis correlates signif-
icantly with the decrease in cGMP during
our follow up of 9 months (r = 0.67, p !
0.01).
Confirming previous reports of elevated
ANP and/or cGMP levels in adults [2–4, 6]
or children [7, 8] on hemodialysis, our study
extends the observation to children by moni-
toring pre- and postdialytic plasma cGMP
levels over a long period. During a 9-month
follow-up, dry weight of studied children was
assessed by clinical signs and/or noninvasive
technical parameters. Over this time period
we found a significant correlation between
percent reduction in body weight and
changes in plasma cGMP levels. According
to the results of previous studies in adults [2,
3] removal of excess body fluid by dialysis
was associated with a significant decrease,
but not with normalization of cGMP in chil-
dren. Since the mean postdialytic cGMP
concentration was below 10 pmol/ml for
each of our patient, we consider this value as
the upper limit of ‘normal range’ in children.
None of these patients exhibiting such a
postdialytic value had echocardiographic
signs of fluid overload. In addition, postdia-
lytic cGMP has been shown to be correlated
with other parameters defining dry body
weight of hemodialysis patients, such as infe-
rior caval vein diameter [9], computed to-
mographic measurements of lung density [9]
and bioimpedance (conductivity measure-
ments) [6].
Although clinical evaluation remains the
first step in the assessment of dry body
weight, it is sometimes difficult to exclude
minor hypervolemia in children. We con-
clude from our data that postdialytic plasma
cGMP is a sensitive and easily accessible
biochemical marker for hypervolemia in pe-
diatric patients on hemodialysis. Determina-
tion of cGMP in addition to the clinical
assessment of hydration state may reduce
the necessity for chest X-ray or invasive pro-
cedures in these patients.
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Fig. 1. A Plasma cGMP levels in 15 children before and after HD. Each point represents the
mean of 9 measurements during 9 months. B Correlation between changes in cGMP
(¢cGMP) and percent reduction in body weight during hemodialysis treatment (n = 15). Each
point represents the mean of 9 measurements during 9 months.
